Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 8/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414481 | 0.90 | TNF (0.51) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL14747649 | 0.90 | TNF (0.51) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL13885908 | 0.88 | TNF (0.56) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL16126909 | 0.88 | LGALS8 (0.52) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL17304977 | 0.88 | TNF (0.56) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL16421742 | 0.88 | TNF (0.56) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL15499729 | 0.88 | TNF (0.56) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL25415041 | 0.84 | TNF (0.58) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL10775003 | 0.84 | TNF (0.58) | TNFMAPK1LGALS8SLC2A1GBA1 | |
| SCHEMBL14747637 | 0.84 | LGALS8 (0.47) | TNFMAPK1LGALS8GBA1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE US LLC (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | HPSE, STS, F11 | TNF 1992/4885MAPK1 2146/4885LGALS8 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.